NEXUS comparison of MiniMed NMX8 with MiniMed 780G
What this study tests
Recruiting European/Israeli study comparing Medtronic's experimental NMX8 AID system with the MiniMed 780G over 12 weeks in people aged 2 and older with insulin-requiring diabetes.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-29.
Most recent recorded citation date: 2025-11-13. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- People aged at least two with insulin-requiring T1D or T2D for at least six months, already using MiniMed 780G with Simplera Sync for at least three months; HbA1c below 11% and total daily insulin 6–250 units. The registry specifies additional safety and training requirements. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The study started on 19 July 2026, is recruiting an estimated 116 participants, and expects completion in March 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union, Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Between-group difference in percentage of sensor glucose time from 70 to 180 mg/dL during the 12-week study phase, tested for noninferiority
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07227805: NEXUS — MiniMed NMX8 versus MiniMed 780G · Trial registry · 2025-11-13 — Registry checked 2026-08-08: RECRUITING after actual start 2026-07-19; estimated n=116; Belgium, Denmark, Israel and Slovenia; completion March 2027. The registry does not use the Vivera brand name.